Why Buy Domino’s Pizza Stock?
When you think of growth stocks, you probably imagine technology…
Buy
72
SHPMY Quote, Financials, Valuation and Earnings
Last price:
$8.29
Seasonality move
:
2.52%
Day range:
$8.29 - $8.29
52-week range:
$5.96 - $8.91
Dividend yield:
4.08%
P/E ratio:
11.00x
P/S ratio:
0.16x
P/B ratio:
0.61x
Volume:
102
Avg. volume:
207
1-year change:
11.97%
Market cap:
$6.1B
Revenue:
$36.8B
EPS (TTM):
$0.75
Analysts' Opinion
-
Consensus RatingShanghai Pharmaceuticals Holding has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, Shanghai Pharmaceuticals Holding has an estimated downside of -- from its current price of $8.29.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $8.29.
Fair Value
-
According to the consensus of 0 analysts, Shanghai Pharmaceuticals Holding has -- downside to fair value with a price target of -- per share.
SHPMY vs. S&P 500
-
Over the past 5 trading days, Shanghai Pharmaceuticals Holding has underperformed the S&P 500 by -0.89% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Shanghai Pharmaceuticals Holding does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Shanghai Pharmaceuticals Holding has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Shanghai Pharmaceuticals Holding reported revenues of $9.8B.
Earnings Growth
-
Shanghai Pharmaceuticals Holding earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Shanghai Pharmaceuticals Holding reported earnings per share of $0.21.
Enterprise value:
8.8B
EV / Invested capital:
--
Price / LTM sales:
0.16x
EV / EBIT:
7.16x
EV / Revenue:
0.23x
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
7.16x
Gross Profit (TTM):
$4.3B
Return On Assets:
1.85%
Net Income Margin (TTM):
1.48%
Return On Equity:
4.92%
Return On Invested Capital:
3.12%
Operating Margin:
3.3%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $35B | $36.2B | $38B | $9B | $9.8B | |
| Gross Profit | $4.5B | $4.5B | $4.3B | $954M | $978.9M | |
| Operating Income | $1.3B | $1.4B | $1.3B | $301.7M | $323.6M | |
| EBITDA | $1.4B | $1.3B | $1.2B | $358.7M | $336.3M | |
| Diluted EPS | $1.27 | $0.85 | $0.75 | $0.22 | $0.21 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $15.8B | $18.2B | $20.7B | $22.6B | $24.8B | |
| Total Assets | $21.8B | $25.2B | $27.3B | $29.2B | $31.9B | |
| Current Liabilities | $11.9B | $14.4B | $15.1B | $16.8B | $18.5B | |
| Total Liabilities | $14B | $16.3B | $16.6B | $18.2B | $20B | |
| Total Equity | $7.8B | $9B | $10.8B | $11B | $11.9B | |
| Total Debt | $4.6B | $5.2B | $5.3B | $6.2B | $6.9B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -$233.8M | -$71.6M | |
| Cash From Investing | -$2.3B | -$215.4M | $112.2M | -$41.4M | -$232.7M | |
| Cash From Financing | $2.4B | -$310.9M | -$334.5M | -$345.8M | -$504.1M | |
| Free Cash Flow | -- | -- | -- | -$334.9M | -$134.3M | |
SHPMY
Sector
Market Cap
$6.1B
--
Price % of 52-Week High
92.97%
--
Dividend Yield
4.08%
--
Shareholder Yield
--
--
1-Year Price Total Return
11.97%
--
Beta (5-Year)
0.610
--
Dividend yield:
4.08%
Annualized payout:
$0.42
Payout ratio:
88.12%
Growth streak:
1 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$8.35
200-day SMA
Buy
Level
$7.58
Bollinger Bands (100)
Buy
Level
6.97 - 8.41
Chaikin Money Flow
Buy
Level
164.7K
20-day SMA
Buy
Level
$8.26
Relative Strength Index (RSI14)
Buy
Level
50.88
ADX Line
Buy
Level
32.54
Williams %R
Neutral
Level
-65.9524
50-day SMA
Buy
Level
$8.19
MACD (12, 26)
Buy
Level
0.04
25-day Aroon Oscillator
Buy
Level
4
On Balance Volume
Sell
Level
-101.3K
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (1.9884)
Sell
CA Score
(Annual)
Level (-0.5595)
Buy
Beneish M-Score
(Annual)
Level (-2.3803)
--
Momentum Score
Level (--)
Buy
Ohlson Score
Level (-0.0681)
Buy
Piotroski F Score
(Annual)
Level (4)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Shanghai Pharmaceuticals is the second-largest medical distributor in China by revenue. It is vertically integrated and provides healthcare services in research and development, manufacturing, distribution, and retail. As of 2023, medical distribution is the largest segment, accounting for 89.8% of total revenue. It also has coverage of 31 provinces and cities nationwide.
Stock Forecast FAQ
In the current month, SHPMY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SHPMY average analyst price target in the past 3 months is --.
-
Where Will Shanghai Pharmaceuticals Holding Stock Be In 1 Year?
According to analysts, the consensus estimate is that Shanghai Pharmaceuticals Holding share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Shanghai Pharmaceuticals Holding?
Analysts are divided on their view about Shanghai Pharmaceuticals Holding share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Shanghai Pharmaceuticals Holding is a Sell and believe this share price will rise from its current level to --.
-
What Is Shanghai Pharmaceuticals Holding's Price Target?
The price target for Shanghai Pharmaceuticals Holding over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SHPMY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Shanghai Pharmaceuticals Holding is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of SHPMY?
You can purchase shares of Shanghai Pharmaceuticals Holding via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Shanghai Pharmaceuticals Holding shares.
-
What Is The Shanghai Pharmaceuticals Holding Share Price Today?
Shanghai Pharmaceuticals Holding was last trading at $8.29 per share. This represents the most recent stock quote for Shanghai Pharmaceuticals Holding. Yesterday, Shanghai Pharmaceuticals Holding closed at $8.29 per share.
-
How To Buy Shanghai Pharmaceuticals Holding Stock Online?
In order to purchase Shanghai Pharmaceuticals Holding stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Companies Are In The VanEck Semiconductor ETF?
There’s a lot to love about the VanEck Semiconductor ETF,…
How High Can Palantir Stock Go?
Palantir Technologies (NASDAQ:PLTR) has been one of the undisputed victors…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 121x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Sell
39
DOGZ alert for Jan 4
Dogness (International) [DOGZ] is down 20.52% over the past day.
Buy
66
DMRC alert for Jan 4
Digimarc [DMRC] is up 16.19% over the past day.
Sell
39
MSTR alert for Jan 4
MicroStrategy [MSTR] is up 13.33% over the past day.
